GP-39 Inhibitors
GP-39, also known as chitinase 3-like protein 1 (CHI3L1), is a glycoprotein belonging to the chitinase protein family. It plays crucial roles in various biological processes, including inflammation, tissue remodeling, and immune response modulation. GP-39 is primarily secreted by activated macrophages, neutrophils, and various other cell types in response to inflammatory stimuli. Its expression is upregulated in numerous pathological conditions such as asthma, rheumatoid arthritis, and cancer, suggesting its involvement in disease pathogenesis.
Inhibition of GP-39 involves targeting its enzymatic activity or modulating its signaling pathways to attenuate its effects. Mechanistically, inhibition strategies may involve small molecule inhibitors that directly bind to the active site of GP-39, blocking its enzymatic function. Additionally, inhibition can occur through interference with downstream signaling pathways activated by GP-39, thereby mitigating its inflammatory and tissue remodeling effects. Targeting GP-39 inhibition holds promise for the development of novel interventions for inflammatory diseases and cancer. Further research into the precise mechanisms of GP-39 inhibition and its downstream effects is warranted to fully elucidate its abilities and applications.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
A-769662 | 844499-71-4 | sc-203790 sc-203790A sc-203790B sc-203790C sc-203790D | 10 mg 50 mg 100 mg 500 mg 1 g | $184.00 $741.00 $1076.00 $3417.00 $5304.00 | 23 | |
AMP-activated protein kinase (AMPK) activator, indirectly influences GP-39 through modulation of energy metabolism and downstream signaling pathways. | ||||||
GW 9662 | 22978-25-2 | sc-202641 | 5 mg | $70.00 | 30 | |
Peroxisome proliferator-activated receptor gamma (PPARγ) antagonist, potentially affects GP-39 expression by inhibiting PPARγ-mediated transcriptional regulation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
p38 mitogen-activated protein kinase (MAPK) inhibitor, influences GP-39 indirectly by suppressing the p38 MAPK pathway, which may be linked to GP-39 regulation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Phosphoinositide 3-kinase (PI3K) inhibitor, can modulate GP-39 through the PI3K/Akt signaling pathway, affecting downstream targets involved in GP-39 expression or activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
c-Jun N-terminal kinase (JNK) inhibitor, influences GP-39 indirectly by suppressing the JNK pathway, which may intersect with signaling cascades related to GP-39 modulation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
PI3K inhibitor, can influence GP-39 through the PI3K/Akt pathway, which plays a role in regulating various cellular processes linked to GP-39 expression or activity. | ||||||
LY 303511 | 154447-38-8 | sc-202215 sc-202215A | 1 mg 5 mg | $67.00 $278.00 | 3 | |
Structural analog of LY294002, with similar PI3K inhibitory properties, affecting GP-39 through modulation of the PI3K/Akt signaling axis. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
NF-κB inhibitor, indirectly influences GP-39 by suppressing NF-κB signaling, which can intersect with pathways related to GP-39 expression or activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
MEK1 inhibitor targeting the MAPK/ERK pathway, potentially modulating GP-39 indirectly by altering downstream effectors within this signaling cascade. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
TGF-β type I receptor inhibitor, indirectly affects GP-39 by modulating TGF-β signaling, which may intersect with pathways related to GP-39 expression or activity. | ||||||